M&A Deal Summary |
|
|---|---|
| Date | 2014-09-24 |
| Target | Civitas Therapeutics |
| Sector | Life Science |
| Buyer(s) | Acorda Therapeutics |
| Sellers(s) | Bay City Capital |
| Deal Type | Add-on Acquisition |
| Deal Value | 525M USD |
| Advisor(s) | J.P. Morgan Securities BofA Securities (Financial) Ropes & Gray (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1995 |
| Sector | Life Science |
| Employees | 102 |
| Revenue | 118M USD (2023) |
Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis and related neurological conditions such as spinal cord injury (SCI). Acorda Therapeutics was founded in 1995 and is headquartered in Pearl River, New York.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 4 |
| Sector (Life Science) | 3 of 4 |
| Type (Add-on Acquisition) | 3 of 4 |
| State (Massachusetts) | 1 of 1 |
| Country (United States) | 3 of 3 |
| Year (2014) | 1 of 1 |
| Size (of disclosed) | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-07-09 |
NeurogesX
San Mateo, California, United States NeurogesX, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients' quality of life. NeurogesX was founded in 1998 and is based in San Mateo, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-01-19 |
Biotie Therapies
Turku, Finland Biotie Therapies Corp. is a biopharmaceutical company primarily focused on developing therapeutics for central nervous system disorders. Its pipeline includes product candidates designed to address unmet medical needs in Parkinson’s disease and related dementia, other neurodegenerative indications and primary sclerosing cholangitis, an orphan fibrotic liver disease. |
Buy | $363M |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 1.3B USD |
| Size | Large |
| Type | Sector Focused |
Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 51 of 62 |
| Sector (Life Science) | 35 of 45 |
| Type (Add-on Acquisition) | 27 of 31 |
| State (Massachusetts) | 5 of 8 |
| Country (United States) | 49 of 59 |
| Year (2014) | 3 of 6 |
| Size (of disclosed) | 4 of 18 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-08-01 |
Vtesse
Gaithersburg, Maryland, United States Vtesse, Inc. is a disease company focused on developing drugs for patients suffering from diseases that are under-served. Vtesse is based in Gaithersburg, Maryland. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-10-03 |
Dermira
Menlo Park, California, United States Dermira, Inc. is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira was founded in 2010 and is based in Menlo Park, California. |
Sell | - |
